A French study points to an increased risk of menstrual disorders

The risk of menstrual disorders is slightly increased during the three months following administration of an anti-Covid messenger RNA vaccine, a study released by French health authorities on Wednesday 24 January suggests, while such a link remains debated in the scientific community.

education “Indicates a 20% increased risk of heavy menstrual bleeding requiring hospital treatment within 1 to 3 months” After receiving the Pfizer or Moderna vaccine for the first time, the Epi-Fhare organization, which links the Medicines Authority (ANSM) and Social Security, summarizes in a press release.

A risk that lasts for three months and then disappears

Since the start of the anti-Covid vaccination campaign almost two and a half years ago, many women have reported disruptions in their menstrual cycles. Based on these statements, the European Medicines Agency (EMA) significantly included the presence of heavy menstrual bleeding as a potential side effect of the messenger RNA vaccine, which is from Pfizer/BioNTech and Moderna.

However, studies on this topic remain conflicting and AP-Fare provides arguments in favor of the existence of such a link. Researchers identified the vaccination status of thousands of women hospitalized for heavy menstrual bleeding in 2021 and 2022. They compared their condition with a control group of women who were not treated for this reason.

They concluded that the risk of such menstrual irregularities is slightly higher when a woman receives the Moderna or Pfizer vaccine for the first time, each given in two successive doses. The risk lasts for three months and then, even after a subsequent booster dose, disappears.